News

BS-102 selected as a promising cancer nanomedicine candidate by NCL

Author
biosynec
Date
2018-08-20 03:30
Views
95
https://nanolab.cancer.gov/sites/default/files/August%202018.pdf
https://www.bio-synectics.com/gnuboard4/bbs/link.php?bo_table=news&wr_id=15&no=2&page=0

August 2018 Awardees Announced - Nanotechnology Characterization Laboratory-

Each quarter the NCL accepts the most promising cancer nanomedicine candidates into its Assay Cascade characterization and testing program. Nanomedicines accepted into the program will undergo a rigorous evaluation that may include sterility and endotoxin testing, physicochemical characterization, in vitro hemato- and immunotoxicity, and in vivo studies to evaluate safety, efficacy and pharmacokinetics. The studies are tailored to each individual nanomedicine and are designed to promote the clinical translation of these novel therapies. All studies are conducted free of charge for Awardees.

This quarter’s awardees are Prof. Zheng-Rong Lu, Case Western Reserve University; Prof. Jordan Green, Johns Hopkins University; and BioSynectics, Inc.

[Published August, 2018]


https://ncl.cancer.gov/about-ncl/about-us

The National Cancer Institute founded the NCL in collaboration with FDA and NIST as a public-private partnership to accelerate the development of promising nanotech therapies and diagnostics. The NCL’s initial mission was to develop an “Assay Cascade” of scientific tests that would help determine the reproducibility, safety, and efficacy of nanomedicines to facilitate regulatory review. NCL has helped several nanomedicine formulations enter and progress through clinical trials, including nanoformulations of small molecules, peptides, proteins, siRNAs and plasmids. NCL's years of running studies on multiple nanomaterial formulations has allowed us to accumulate tremendously nuanced knowledge about what works and what doesn't work for nanomedicines. While other academic, industry, or government labs have specialized expertise in one or even a few particular types of nanomaterials, NCL is the only lab with experience testing the wide variety of platforms used in nanomedicine. Since it was founded in 2004, the NCL has tested more than 350 nanomaterials, including almost every type of nanoparticle used in biomedical R&D: metallic, liposomes, polymers, proteins, micelles, DNA and RNA nanostructures, carbon nanotubes, etc.

NCL conducts free preclinical characterization, pharmacokinetic, efficacy, and toxicity testing of promising nanotech cancer therapeutics and diagnostics using the “Assay Cascade”.